After 50 years, St. Michael’s Hospital remains at the forefront of kidney care
Our history of innovations has been remarkable. But we never rest on our laurels. St. Michael’s clinicians and scientists are always at the forefront of new discovery.
St. Michael’s clinicians and scientists are always at the forefront of new discovery.
- St. Michael’s helped solve the problem of incompatible donors and recipients. This is how it works: family members and friends who wish to donate a kidney but aren’t compatible with their loved one are matched with another donor-recipient pair with the same problem. A “swap” is made so that each recipient gets a kidney. Before this program, 20 per cent of living donors were excluded because they didn’t match the intended recipient.
- We are the only transplant centre in North America to offer blood-type-incompatible transplants with Glycosorb®, a technology that enables patients to accept a kidney from a donor with a different blood type.
- St. Michael’s was the first transplant program in Ontario to utilize minimally invasive surgery on living kidney donors. Smaller incisions mean less trauma, less scarring, less pain and reduced recovery time.
- We have North America’s most ethnically diverse transplant population. We were the first in the world to discover that South Asians experience a higher risk of cardiac events following a transplant, resulting in a change of protocols for this population. And we have a robust international program that has brought living donors from 81 countries. In one case, it took us a mere 21 days to bring a donor from overseas and perform the transplant on our patient here in Canada.
- We conducted the most extensive clinical research in Canada on a new drug formulation: Tacrolimus is an anti-rejection medication essential for transplant patients. As a result of our work, once-daily tacrolimus has been helping kidney transplant patients since 2005.
- We are conducting the world’s largest clinical trial on dialysis start times: The trial STARRT-AKI will determine the optimal time for those with acute kidney injury, a patient group with a high mortality rate, to begin dialysis. St. Michael’s nephrologist Dr. Ron Wald is co-leading the international trial which includes almost 3,000 patients in 14 different countries. The trial will conclude in mid-2019.
A transformational gift
“It is truly so exciting and well overdue to have the world-leading BARLO MS Centre right here in Toronto.” – Betsy Fruitman.Read article
Young mother and MS patient hits the road again
Thanks to the Elizabeth S. Barford MS Patient Comfort Fund, Rosani Christy-Sarva was able to modify the family van and regain some independence.Read article
Giulia Muzzi makes her dreams come true
University student Giulia Muzzi was devastated when she found out she had MS. But the care she received at St. Michael’s not only helped her realize her goal of becoming a teacher, but inspired her to raise funds for MS research.Read article
Erin Truax is determined to help St. Michael’s stop MS in its tracks
Erin Truax was diagnosed with MS three years ago. She continues to live life with high energy, and credits St. Michael’s Hospital for its great care.Read article
Women in medical leadership: Where to now?
Dr. Carolyn Snider, chief of Emergency Medicine, on why women still lag behind men in medical leadership and what can be done about it.Read article
St. Michael’s staff stop at nothing to make wishes come true
The Three Wishes program brought nursing and spiritual care staff together for an ICU wedding that honours end-of-life.Read article